

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-100279-PIP01-21

Scope of the Application

Active Substance(s)

Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide

Condition(s)

Diabetic retinopathy

Pharmaceutical Form(s)

Powder for solution for infusion

Route(s) of Administration

Intravitreal use

Name / Corporate name of the PIP applicant

Boehringer Ingelheim International GmbH

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Boehringer Ingelheim International GmbH submitted to the licensing authority on 08/10/2021 15:14 BST an application for a Waiver

The procedure started on 18/02/2022 09:58 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

The granting of a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100279-PIP01-21

Of 03/03/2022 08:28 GMT

On the adopted decision for Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide (MHRA-100279-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide, Powder for solution for infusion , Intravitreal use .

This decision is addressed to Boehringer Ingelheim International GmbH, Binger Strasse 173, Ingelheim am Rhein, Germany, 55216

ANNEX I

1. Waiver

1.1 Condition:

Treatment of diabetic retinopathy The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Powder for solution for infusion Route(s) of administration: Intravitreal use Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not Applicable

2.2 Indication(s) targeted by the PIP:

Not Applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not Applicable

2.4 Pharmaceutical Form(s):

Not Applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	